Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders

References

• Rosenberg SD, Swanson JW, Wolford GL et al. Blood-borne infections and persons with mental illness: the five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr. Serv.54(6), 827–835 (2003).
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med.341, 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin. Infect. Dis.40, S339–S345 (2005).
   PubMed Web of Science ®Google Scholar
• Sherman KE, New paradigms in the management of hepatitis C virus co-infections. Nat. Clin. Pract. Gastroenterol. Hepatol.4(Suppl. 1), S10–S16 (2007).
   PubMedGoogle Scholar
• Management of hepatitis C. NIH Consens. Statement15(3), 1–41 (1997).
   Google Scholar
• Loftis JM, Hauser P. Hepatitis C in patients with psychiatric disease and substance abuse: screening strategies and comanagement models of care. Curr. Hepat. Rep.2, 93–100 (2003).
   Google Scholar
• Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction99, 1167–1175 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Fiellin DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am. J. Addict.13, 1–20 (2004).
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Loftis JM, Hauser P et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J. Urban Health81(4), 719–734 (2004).
   PubMed Web of Science ®Google Scholar
• Jeffrey GP, MacQuillan G, Chua F et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology45(1), 111–117 (2007).
   PubMed Web of Science ®Google Scholar
• Witthoeft T, Fuchs M, Ludwig D. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J. Gastroenterol.13(4), 579–584 (2007).
   PubMed Web of Science ®Google Scholar
• Guadagnino V, Trotta MP, Montesano F et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction102(3), 423–431 (2007).
   PubMed Web of Science ®Google Scholar
• Grebely J, Raffa JD, Meagher C et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J. Gastroenterol. Hepatol.22(9), 1519–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Huber M, Weber R, Oppliger R et al. Interferon α-2a plus ribavirin 1,000/1,200 mg versus interferon α-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection33(1), 25–29 (2005).
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology40(1), 120–124 (2004).
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroenterol.98(10), 2281–2288 (2003).
   PubMed Web of Science ®Google Scholar
• Robaeys G, Van Vlierberghe H, Mathei C et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol.18(2), 159–166 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology37, 443–451 (2003).
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Wright T, Rossi S et al. Peginterferon α-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin. Pharmacol. Ther.77(3), 214–224 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon α-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J. Clin. Pharmacol.47(5), 604–612 (2007).
   PubMed Web of Science ®Google Scholar
• Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon α-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin. Ther.29(1), 131–138 (2007).
   PubMed Web of Science ®Google Scholar
• Freedman K, McLaughlin P, Strong P. Treatment of hepatitis C infected substance abusers within a community-based, outpatient methadone maintenance program. Am. J. Gastroenterol.100(9), S111 (2005).
   Google Scholar
• Matthews G, Kronberg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin. Infect. Dis.40(Suppl. 5), S325–S329 (2005).
   PubMed Web of Science ®Google Scholar
• Rifai MA, Moles JK, Lehman LP, Van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics47(2), 112–121 (2006).
   PubMed Web of Science ®Google Scholar
• Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur. Addict. Res.13(4), 216–221 (2007).
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Gandhi RT, Walsh JP et al. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics48, 405–411 (2007).
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis management and treatment of hepatitis C (AASLD Practice Guidelines). Hepatology39(4), 1147–1171 (2004).
   PubMed Web of Science ®Google Scholar
• Rifai MH, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr. Treat. Options Gastroenterol.9, 508–619 (2006).
   PubMedGoogle Scholar
• Schaefer M, Schwaiger M, Garkisch AS et al. Prevention of interferon-α associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol.42, 793–798 (2005).
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology37, 433–451 (2003).
   Google Scholar
• Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C treatment for people with severe mental illness. Psychosomatics47, 93–107 (2006).
   PubMed Web of Science ®Google Scholar
• McGovern B, Fiore J, Wurcel A et al. Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin. Infect. Dis.41(Suppl. 1), S56–S62 (2005).
   PubMed Web of Science ®Google Scholar
• Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr. Serv.57(4), 570–572 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer M, Hinzpeter A, Mohmand A et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-α and ribavirin: response and psychiatric side effects. Hepatology46(4), 991–998 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin. Infect. Dis.40(Suppl. 5), S355–S361 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to HCV treatment in recovering heroin users maintained on methadone. J. Subst. Abuse Treat.29, 159–165 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvestre DL. Approaching treatment for hepatitis C virus infection in substance users. Clin. Infect. Dis.41(Suppl. 1), S79–S82 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur. J. Gastroenterol. Hepatol.18(10), 1057–1063 (2006).
   PubMed Web of Science ®Google Scholar
• Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A (for the Nocchiero Study Group). Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig. Liver Dis.38(2), 119–124 (2006).
   PubMedGoogle Scholar
• Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend.88(1), 49–53 (2007).
   PubMed Web of Science ®Google Scholar
• Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int. J. Drug Policy18(5), 437–443 (2007).
   PubMed Web of Science ®Google Scholar
• Berk SI, Litwin AH, Du Y, Cruikshank G, Gourevitch MN, Arnsten JH. False reduction in serum methadone concentrations by BD Vacutainer® Serum Separator Tubes (SST™). Clin. Chem.52(10), 1972–1974 (2006).
   PubMed Web of Science ®Google Scholar